Moderna/$MRNA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Moderna
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Ticker
$MRNA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
5,800
ISIN
US60770K1079
Website
Moderna Metrics
BasicAdvanced
$11B
-
-$8.73
2.23
-
Price and volume
Market cap
$11B
Beta
2.23
52-week high
$158.82
52-week low
$23.15
Average daily volume
12M
Financial strength
Current ratio
4.218
Quick ratio
3.916
Long term debt to equity
6.974
Total debt to equity
7.401
Interest coverage (TTM)
-196.26%
Management effectiveness
Return on assets (TTM)
-15.84%
Return on equity (TTM)
-29.34%
Valuation
Price to revenue (TTM)
3.305
Price to book
1.05
Price to tangible book (TTM)
1.05
Price to free cash flow (TTM)
-2.603
Growth
Revenue change (TTM)
-38.35%
Earnings per share change (TTM)
-44.29%
3-year revenue growth (CAGR)
-48.00%
3-year earnings per share growth (CAGR)
-36.46%
What the Analysts think about Moderna
Analyst ratings (Buy, Hold, Sell) for Moderna stock.
Moderna Financial Performance
Revenues and expenses
Moderna Earnings Performance
Company profitability
Moderna News
AllArticlesVideos
Moderna agrees to true placebo-controlled trial of new COVID vaccine, Kennedy says
Reuters·2 days ago
Moderna, favored by the first Trump administration for its Covid-19 vaccine, is now in trouble as Trump 2.0 shifts its position on vaccine-making
WSJ·3 days ago
Top Stock Movers Now: Ford, Cleveland-Cliffs, Moderna, and More
Investopedia·3 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Moderna stock?
Moderna (MRNA) has a market cap of $11B as of June 05, 2025.
What is the P/E ratio for Moderna stock?
The price to earnings (P/E) ratio for Moderna (MRNA) stock is 0 as of June 05, 2025.
Does Moderna stock pay dividends?
No, Moderna (MRNA) stock does not pay dividends to its shareholders as of June 05, 2025.
When is the next Moderna dividend payment date?
Moderna (MRNA) stock does not pay dividends to its shareholders.
What is the beta indicator for Moderna?
Moderna (MRNA) has a beta rating of 2.23. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.